Bionor S Mission Is To Enable The Immune System To Fight Hiv Infectionbionor Is The First Companywhich Has Successfully Completed A Clinical Trial Using The Shock And Kill Approachthereby Creating A Strong Foundation For Further Advancing Its Therapeutic Vaccine Vacc 4X And Vacc C5 In Combination With Other Agents Towards A Functional Curethe Company Believes It Has First Mover Potential Based On Clinical Results To Date And Early Adoption Of The Shock And Kill Strategyin December 2015Bionor Announced That The Hiv Trial Reduc With Vacc 4X And Romidepsin Successfully Met Its Primary Endpoint By Reducing Latent Hiv Reservoir And Further Demonstrated Control Of Viral Loadbionor Retains Full Ownership Rights To The Hiv Immunotherapy Vacc 4X And Vacc C5I E The Upside Potential From Partnering Or Licensing Remains With The Company
